Option chain shows key data for Apollomics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Apollomics.

Apollomics (NASDAQ:APLM) Stock, Option Chain

Apollomics

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Wall Street

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APLM

NCNC

PRFX

QMMM

TRNR

Dow Dips Over 300 Points; Walmart Raises FY25 Forecast

Tesla Inc. TSLA

Pre-Market Outlook

Movers

AEMD

AREN

ATCH

CMAX

CYCN

ERNA

FLYE

LAZR

LBRT

MNDR

NTLA

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

BATL

HCWB

NGNE

UAVS

Dow Falls 100 Points; Brady Posts Upbeat Results

Apollomics Inc. - Class A Ordinary Shares

Apollomics Inc

Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data

Press Releases

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

General

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Health Care

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Contracts

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

APLMW

CRDL

NIVF

SINT

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Ainos

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Mainz Biomed

Ocean Biomedical

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

EF Hutton

Comments

Apollomics

Apollomics (APLM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga